"Clinical benefit rate" in phase 2 gynecologic cancer trials: implying more than the data support?
Markman
Maurie
M
Department of Gynecologic Medical Oncology, University of Texas MD Anderson Cancer, Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. mmarkman@mdanderson.org
D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D023381:Endpoint Determination; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D016896:Treatment Outcome